文献速递肾癌与肾肿瘤

美国泌尿外科协会肾细胞癌风险分组在嫌色细胞肾细胞癌中的评估

Evaluation of American Urological Association Renal Cell Carcinoma Risk Groups for Chromophobe Renal Cell Carcinoma.
PubMed 文献 · Urology · 2024-08-10

该研究基于1970—2012年单中心257例手术治疗的局限性嫌色细胞肾细胞癌患者,比较排除核分级的改良AUA风险分组与Mayo系统的预测能力。改良AUA与Mayo系统预测无进展生存的c指数分别为0.76和0.75,预测癌症特异性生存的c指数分别为0.77和0.76,两者表现相似。

要点

  • 改良AUA与Mayo风险分组在嫌色细胞肾细胞癌中预测无进展生存的c指数分别为0.76和0.75。
  • 两系统预测癌症特异性生存的c指数分别为0.77和0.76,表现相似。
  • 术后10年无进展生存率为84%,癌症特异性生存率为90%。

核心结论

  • 排除核分级的改良AUA与Mayo风险分层系统在嫌色细胞肾细胞癌中预测无进展生存和癌症特异性生存的c指数相似且稳健。

研究设计与样本

  • 回顾性查询本机构登记数据库,纳入1970—2012年因单侧、散发性、M0期嫌色细胞肾细胞癌接受手术的患者257例。
  • 改良AUA风险分组采用已报告标准但排除核分级,并与纳入淋巴结受累、肾周/肾窦脂肪侵犯及肉瘤样分化的Mayo系统进行比较。
  • 采用Kaplan-Meier法估计无进展生存和癌症特异性生存,采用Cox比例风险回归模型的c指数总结预测能力。

主要发现

  • 39例患者在中位30个月(IQR 5.0-84)出现疾病进展,25例在中位34个月(IQR 15-79)死于嫌色细胞肾细胞癌。
  • 术后10年无进展生存率为84%,癌症特异性生存率为90%。
  • 改良AUA与Mayo风险分组预测无进展生存的c指数分别为0.76和0.75。
  • 改良AUA与Mayo风险分组预测癌症特异性生存的c指数分别为0.77和0.76。

临床怎么用

  • 作者认为,这些模型可基于病理特征用于患者咨询、指导临床医生制定合适的随访路径,并识别有疾病进展风险的患者以纳入辅助全身治疗试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop and compare various models for risk stratification in chromophobe renal cell carcinoma (chrRCC). Models have been developed to predict progression-free (PFS) and cancer-specific survival (CSS) following surgery for localized renal cell carcinoma (RCC). Notably, chromophobe RCC (chrRCC) is not included in American Urological Association (AUA) risk stratification, as nuclear grading is not recommended. METHODS: We queried our institutional registry to identify patients managed surgically for unilateral, sporadic, M0, chrRCC from 1970-2012. AUA risk groups were defined using reported criteria, excluding grade, and were compared to the Mayo system incorporating nodal involvement, perinephric/renal sinus fat invasion, and sarcomatoid differentiation. PFS and CSS were estimated using the Kaplan-Meier method. Predictive ability was summarized using c-indexes from Cox proportional hazard regression models. RESULTS: A total of 257 patients were identified. Thirty-nine patients experienced disease progression at a median 30 months (IQR 5.0-84) and 25 died from chrRCC at a median 34 months (IQR 15-79) following surgery. PFS and CSS rates at 10 years after surgery were 84% and 90%, respectively. C-indexes for modified AUA and Mayo risk groups were similar at 0.76 and 0.75, respectively, for PFS, and 0.77 and 0.76, respectively for CSS. CONCLUSION: The modified AUA and Mayo risk stratification systems have similarly robust c-indexes for PFS and CSS in chrRCC. These models can be used to counsel patients based on pathologic features, inform clinicians on appropriate follow-up pathways, and identify patients at risk of disease progression for enrollment in adjuvant systemic therapy trials.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Britton CJ, Sharma V, Zganjar A, et al. Evaluation of American Urological Association Renal Cell Carcinoma Risk Groups for Chromophobe Renal Cell Carcinoma. Urology. 2024. PMID: 39128633. doi:10.1016/j.urology.2024.07.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。